SABIO-GROUP
Sabio Group , Europe’s leading technology and digital CX service provider, has acquired Fonetic , a leading Spanish provider of cloud-enabled AI voicebots, chatbots and customer behaviour analytics solutions. The announcement strengthens Sabio’s AI and Automation solutions offering, enabling the company’s goal of supporting customers with its own truly innovative range of CX solutions to complement its broad multi-vendor product portfolio.
Since its formation in 2006, Fonetic has established itself as a specialist in the provision of voice recognition, Natural Language Processing (NLP) and Artificial Intelligence-powered voicebot and chatbot solutions. Fonetic solutions help organisations to digitally transform their CX operations. The company currently manages, processes and monitors over 200 million interactions per year for major clients including Generali, Axa, Banco Santander, Endesa, , Linea Directa, Mapfre, Multiasistencia and Vodafone.
“We’re now at the stage where it’s reasonable to expect that almost every customer interaction will soon be fronted by AI in some shape or form, and that AI-enabled capabilities are poised to transform customer experience,” explained Sabio’s CEO Jonathan Gale. “With its proven voicebot, chatbot, customer behaviour analytics and visualisation capabilities, Fonetic directly addresses this challenge. The company not only brings an incredibly talented team but valuable expertise in CX digital transactions that will be an important addition to Sabio’s own IP portfolio.”
“At Fonetic we can demonstrate how our voicebots and chatbots perform at scale. This helps our clients to digitally transform their customer engagement by increasing CX efficiencies while also securing significant increases in customer satisfaction,” added Juan Manuel Soto, Fonetic’s CEO and Founder. “As part of the Sabio Group we can bring our voicebot and chatbot offering to a much broader market, especially as AI and automation adoption within the CX sector is set to accelerate exponentially.”
Fonetic works closely with Generali Spain’s Digital Transformation team, and designed and developed the multichannel Bot for Generali in Spain. Commenting, Generali Spain’s Head of Business Transformation and Control, Enrique Lorente said: “Fonetic’s Bot expertise and design skills are a key factor behind the success of our cognitive Bot - by providing a conversational assistant to our distributors and customers, offering automatic claim management, one of Generali’s key and highly volume processes, and allowing them to use the channel of their choice, in an easy and natural way. We look forward to being part of their continued success.”
Fonetic voicebots and chatbots are bot-agnostic and can be deployed using either the company’s own technology or integrated with third-party NLP assets to get the most out of tools such as Microsoft Bot Framework & Luis, Google Dialogflow, IBM Watson, Nuance’s Nina, Sabio’s own solution flexAnswer, Genesys or home assistants like Alexa and Google Home.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210315005045/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom